Podcasts

Episode 43 | Management of Limited-Stage Small Cell Lung Cancer

We dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining us are leading experts in oncology Zarnie Lwin, Susan Harden and Wei-Sen Lam.

Episode Summary

In this episode, we dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining us are leading experts in oncology Zarnie Lwin, Susan Harden and Wei-Sen Lam.

Together, they explore the significance of the ADRIATIC trial results, debate the role of prophylactic cranial irradiation (PCI) in the treatment of SCLC, and provide insights into ongoing studies that may further improve outcomes for patients. Tune in for a deep dive into the latest research and expert perspectives on this aggressive cancer.

Show Hosts

This episode’s host are:

Associate Professor Zarnie Lwin, OAM, Medical Oncologist at Royal Brisbane Women’s Hospital and the University of Queensland, QLD
Associate Professor Susan Harden, Radiation Oncologist at Peter MacCallum Cancer Centre and Monash Cancer Registries, VIC
Dr. Wei-Sen Lam, Medical Oncologist and TeleHealth lead at Fiona Stanley and Esperance Hospitals, WA

Play Episode 43 | Management of Limited-Stage Small Cell Lung Cancer

More Podcasts

50 – The Role of Liquid Biopsy in Modern Oncology

Podcasts
March 21, 2025

In this episode, Dr. Malinda Itchins, Dr. Annie Wong, and A/Prof Steven Kao discuss the concept of liquid biopsy, its advantages and limitations, and its

49 – Exploring EGFR Exon 20 Insertion Mutations

Podcasts
March 7, 2025

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into

48 – A Conversation with Prof. Michael Boyer

Podcasts
February 6, 2025

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and

47 – Introducing Conversations in Lung Cancer Research

Podcasts
February 6, 2025

In this introductory episode, A/Prof Mel Moore, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.'

46 – Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy

Podcasts
December 13, 2024

Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC

45 – The Case For IO in Early-Stage NSCLC in a Once in a Lifetime World

Podcasts
December 2, 2024

Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.